
Rebecca N Jerome

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5278507/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Recruitment and retention for chronic pain clinical trials: a narrative review. Pain Reports, 2022, 7, e1007.	2.7	3
2	Equipoise and research in the current COVID-19 pandemic. Journal of Clinical and Translational Science, 2021, 5, .	0.6	0
3	Opening doors to clinical trial participation among Hispanics: Lessons learned from the Spanish translation of ResearchMatch. Journal of Clinical and Translational Science, 2021, 5, e46.	0.6	7
4	The Astounding Breadth of Health Disparity: Phenome-Wide Effects of Race on Disease Risk. Journal of the National Medical Association, 2021, 113, 187-194.	0.8	1
5	Uncovering Outcome Disparities of β2 Adrenergic Agonists in Blacks: A Systematic Review. Journal of the National Medical Association, 2021, 113, 8-29.	0.8	4
6	Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases. Frontiers in Genetics, 2021, 12, 707836.	2.3	9
7	Engaging smokers in research: Utility of Facebook in facilitating recruitment to a smoking cessation study. Contemporary Clinical Trials, 2021, 107, 106461.	1.8	5
8	The Recruitment Innovation Center: Developing novel, person-centered strategies for clinical trial recruitment and retention. Journal of Clinical and Translational Science, 2021, 5, e194.	0.6	15
9	Effects of financial incentives on volunteering for clinical trials: A randomized vignette experiment. Contemporary Clinical Trials, 2021, 110, 106584.	1.8	3
10	Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data. Annual Review of Pharmacology and Toxicology, 2020, 60, 333-352.	9.4	39
11	Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use. Drug Safety, 2020, 43, 567-582.	3.2	9
12	Exploring Biologic Predictors of Response Disparities to Atypical Antipsychotics among Blacks: A Quasi-Systematic Review. Ethnicity and Disease, 2020, 30, 229-240.	2.3	5
13	COMPASS: A Pilot Trial of an Early Palliative Care Intervention for Patients With End-Stage Liver Disease. Journal of Pain and Symptom Management, 2019, 58, 614-622.e3.	1.2	38
14	Broad-scale informed consent: A survey of the CTSA landscape. Journal of Clinical and Translational Science, 2019, 3, 253-260.	0.6	5
15	To end disease tomorrow, begin with trials today: Digital strategies for increased awareness of a clinical trials finder. Journal of Clinical and Translational Science, 2019, 3, 190-198.	0.6	2
16	We're not all cut from the same cloth: TAILORing treatments for children with chronic conditions. Journal of Patient-Reported Outcomes, 2019, 3, 25.	1.9	1
17	Understanding What Information Is Valued By Research Participants, And Why. Health Affairs, 2019, 38, 399-407.	5.2	52
18	A Phenome-Wide Association Study Uncovers a Pathological Role of Coagulation Factor X during Acinetobacter baumannii Infection. Infection and Immunity, 2019, 87, .	2.2	8

Rebecca N Jerome

#	Article	IF	CITATIONS
19	Development of the Initial Surveys for the All of Us Research Program. Epidemiology, 2019, 30, 597-608.	2.7	35
20	Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. Targeted Oncology, 2018, 13, 61-68.	3.6	8
21	Using Human â€~Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors. Drug Safety, 2018, 41, 303-311.	3.2	22
22	Connecting the public with clinical trial options: The ResearchMatch Trials Today tool. Journal of Clinical and Translational Science, 2018, 2, 253-257.	0.6	15
23	Patient and healthcare provider views on a patient-reported outcomes portal. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1470-1480.	4.4	23
24	Advocating for mutually beneficial access to shelved compounds. Future Medicinal Chemistry, 2018, 10, 1395-1398.	2.3	6
25	Reply to Ward and Colleagues' Comment on "Using Human Experiments of Nature to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors― Drug Safety, 2018, 41, 1101-1101.	3.2	1
26	Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. Assay and Drug Development Technologies, 2017, 15, 113-119.	1.2	30
27	When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. Assay and Drug Development Technologies, 2017, 15, 354-361.	1.2	4
28	Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously III Patients. Academic Medicine, 2016, 91, 305-309.	1.6	14
29	Genetic epidemiology of pelvic organ prolapse: a systematic review. American Journal of Obstetrics and Gynecology, 2014, 211, 326-335.	1.3	62
30	Methods for systematic reviews of administrative database studies capturing health outcomes of interest. Vaccine, 2013, 31, K2-K6.	3.8	26
31	Exploring clinician adoption of a novel evidence request feature in an electronic medical record system. Journal of the Medical Library Association: JMLA, 2008, 96, 34-41.	1.7	11
32	Expert synthesis of the literature to support critical care decision making. Journal of the Medical Library Association: JMLA, 2006, 94, 376-81.	1.7	3